Company* (Country; Symbol)

Company* (Country; Symbol)

Type/Product Area

Terms/Details (Date)

Avidex Ltd.* (UK)

Dow Chemical Co. (NYSE:DOW)

Agreement in which Avidex will use its monoclonal T-cell receptors with technology from Dow Chemical to create biotargeted radio-pharmaceuticals for cancer

Dow's ChelaMed radiopharmaceutical services will be used to attach a therapeutic radioisotope to a targeted mTCR; the first effort will focus on Avidex's mTCR product, EsoDex, to further enhance the targeted radiopharmaceutical for lung and bladder cancer (9/2)

CalbaTech Inc.*

Individual scientist

License to technology for the delivery of stem cells to diseased areas of the heart

CalbaTech licensed the device from Jason Van Tassell; financial terms were not disclosed (10/14) 

Genencor International Inc. (GCOR)

Cargill Dow LLC*

Agreement to create advanced enzyme systems for a biomass project supported by the U.S. Department of Energy

The project is a step toward advancing the biorefinery concept ultimately to reduce dependence on fossil carbon sources, lower greenhouse gas emissions and stimulate rural economies (9/8)

Intrinsic Bioprobes Inc.*

Beavis Informatics Ltd.* (Canada)

Parternship to develop an analysis and informatics platform for protein characterization

Beavis will develop an informatics system suited to Intrinsic's MASSAY system; financial terms were not disclosed (10/15)

Promega Corp.*

Corning Inc. (NYSE:GLW)

Alliance to co-develop, co- manufacture and co-market a fully optimized system of reagents for self-printing microarrays

Both parties expect to co-produce a product called Pronto! Plus, following Corning's entry into the reagent market with its Pronto! Microarray Reagent Systems for validation, printing and hybridization (9/8)

Qiagen NV (the Netherlands; QGENF)

Thermo Electron Corp. (NYSE:TMO)

Exclusive agreement to co-market and co-promote Thermo Electron's King- Fisher instrumentation technology together with Qiagen's magnetic bead-based nucleic acid separation and purification technology

It will be used in nucleic acid-based applications in research and molecular diagnostics (9/22)

Sunol Molecular Corp.*

Dow Chemical Co. (NYSE:DOW)

Collaboration to produce a therapeutic protein in transgenic plants and to compare its properties with those of the same antibody produced in mammalian cell culture

Dow will express in plants an anti-tissue factor antibody developed by Sunol for multiple types of cancer (9/17)

Notes:

# This chart does not include agreements that involve agricultural product development.

* Private companies are indicated with an asterisk.

Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market.

NYSE = New York Stock Exchange.